Have your own idea? Try our Stock Screener
Markets has moved to Discover
You can now access Markets by navigating to Discover and selecting Markets.
U.S. Biotech Industry Analysis
UpdatedSep 20, 2024
DataAggregated Company Financials
Companies557
- 7D1.4%
- 3M7.8%
- 1Y23.1%
- YTDn/a
In the last week, the Biotech industry is up 1.4%, with Amgen up 1.8%. In the same time, Summit Therapeutics was down 16%. In the last 12 months, the industry was up 23%. As for the next few years, earnings are expected to grow by 28% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 20 Sep 2024 | US$919.7b | US$113.2b | -US$35,956,842,944.72 | 22.1x | -25.6x | 8.1x |
| Sun, 18 Aug 2024 | US$883.1b | US$113.2b | -US$35,819,260,655.83 | 22.3x | -24.7x | 7.8x |
| Tue, 16 Jul 2024 | US$1.2t | US$164.5b | -US$28,103,794,830.82 | 29x | -42.5x | 7.3x |
| Thu, 13 Jun 2024 | US$1.2t | US$164.5b | -US$28,092,824,135.28 | 28x | -41.1x | 7x |
| Sat, 11 May 2024 | US$1.1t | US$164.6b | -US$26,942,623,519.83 | 23.3x | -41.5x | 6.8x |
| Mon, 08 Apr 2024 | US$1.1t | US$164.4b | -US$23,377,298,863.03 | 21.3x | -48.3x | 6.9x |
| Wed, 06 Mar 2024 | US$1.2t | US$167.9b | -US$21,336,854,000.78 | 16.1x | -55.9x | 7.1x |
| Fri, 02 Feb 2024 | US$1.4t | US$204.7b | -US$22,768,331,138.00 | 19x | -63.6x | 7.1x |
| Sun, 31 Dec 2023 | US$1.4t | US$204.9b | -US$22,199,644,413.00 | 19.8x | -62.6x | 6.8x |
| Tue, 28 Nov 2023 | US$1.2t | US$204.8b | -US$22,010,873,467.00 | 18.7x | -55.7x | 6x |
| Thu, 26 Oct 2023 | US$1.2t | US$207.4b | -US$13,064,474,784.00 | 16.4x | -92.7x | 5.8x |
| Sat, 23 Sep 2023 | US$1.3t | US$207.5b | -US$12,879,348,159.00 | 17.1x | -97.9x | 6.1x |
| Mon, 21 Aug 2023 | US$1.3t | US$207.6b | -US$12,372,676,716.00 | 17.6x | -102.2x | 6.1x |
| Wed, 19 Jul 2023 | US$1.1t | US$186.7b | -US$15,964,743,132.00 | 12.8x | -71.3x | 6.1x |
| Fri, 16 Jun 2023 | US$1.2t | US$186.3b | -US$15,880,859,492.00 | 12.2x | -72.5x | 6.2x |
| Sun, 14 May 2023 | US$1.2t | US$191.7b | -US$12,222,188,637.00 | 13.8x | -94.4x | 6x |
| Tue, 11 Apr 2023 | US$1.2t | US$198.2b | -US$3,345,249,969.00 | 13.8x | -346.3x | 5.8x |
| Thu, 09 Mar 2023 | US$1.1t | US$199.1b | -US$4,824,949,147.00 | 15x | -232.6x | 5.6x |
| Sat, 04 Feb 2023 | US$1.2t | US$203.6b | US$1.7b | 15.6x | 703.6x | 5.7x |
| Mon, 02 Jan 2023 | US$1.2t | US$203.5b | US$1.7b | 14.3x | 667.5x | 5.7x |
| Wed, 30 Nov 2022 | US$1.1t | US$202.2b | US$1.3b | 14.6x | 876.7x | 5.5x |
| Fri, 28 Oct 2022 | US$1.1t | US$205.5b | US$7.3b | 14x | 147.6x | 5.3x |
| Sun, 25 Sep 2022 | US$1.0t | US$206.0b | US$5.6b | 13.9x | 182.3x | 4.9x |
| Tue, 23 Aug 2022 | US$1.1t | US$206.2b | US$7.2b | 15.6x | 147.4x | 5.2x |
| Thu, 21 Jul 2022 | US$1.1t | US$211.6b | US$10.7b | 17.1x | 101.1x | 5.1x |
| Sat, 18 Jun 2022 | US$922.9b | US$212.2b | US$10.9b | 14.8x | 84.4x | 4.3x |
| Mon, 16 May 2022 | US$993.9b | US$212.0b | US$10.6b | 15.6x | 94.1x | 4.7x |
| Wed, 13 Apr 2022 | US$1.3t | US$226.8b | US$14.9b | 18.2x | 85.4x | 5.6x |
| Fri, 11 Mar 2022 | US$1.2t | US$222.2b | US$10.6b | 19x | 114.6x | 5.5x |
| Sun, 06 Feb 2022 | US$1.3t | US$216.1b | US$6.6b | 21.5x | 190.2x | 5.8x |
| Tue, 04 Jan 2022 | US$1.4t | US$211.9b | US$2.8b | 26x | 519.5x | 6.8x |
| Thu, 02 Dec 2021 | US$1.5t | US$212.0b | US$3.1b | 24.9x | 469.3x | 6.9x |
| Sat, 30 Oct 2021 | US$1.5t | US$195.9b | -US$3,061,505,326.00 | 25.3x | -491.2x | 7.7x |
| Mon, 27 Sep 2021 | US$1.6t | US$196.4b | -US$2,419,608,414.00 | 24.9x | -653.6x | 8.1x |
Price to Earnings Ratio
-653.6x
Current Industry PE
- Investors are optimistic on the American Biotechnology industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.2x is lower than the industry's current PS ratio of 8.1x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have deteriorated over the last three years.
- Revenues have also declined 17% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Comparison
How does U.S. Biotech compare with similar industries?
| US Market | 2.56% | |
| Healthcare | 0.34% | |
| Biotech | 1.41% | |
| Biotech | 1.41% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| AMGN Amgen | US$335.95 | 1.8% +US$3.2b | 24.7% | PE57.7x | |
| ASND Ascendis Pharma | US$153.43 | 34.8% +US$2.3b | 60.8% | PS24.8x | |
| NUVL Nuvalent | US$103.25 | 26.4% +US$1.9b | 139.2% | PB11.3x | |
| ALNY Alnylam Pharmaceuticals | US$276.33 | 5.6% +US$1.9b | 58.9% | PS15.1x | |
| SGEN Seagen | US$228.74 | 4.5% +US$1.8b | 76.5% | PS18.8x |
